Skip to main content
. 2020 Apr 16;50(3):135–145. doi: 10.5051/jpis.2020.50.3.135

Table 4. Serum parameters of the subgroups.

Variable Ch (n=16) Cg (n=24) Cp (n=28) H1h (n=14) H1g (n=23) H1p (n=29) H2h (n=14) H2g (n=20) H2p (n=23)
TC (mg/dL) 146.50 (113–191) 170.00 (140.00–197.00) 164.00 (92.00–200.00) 207.00a,b,c) (176–241) 221.00a,b,c,d) (202.00–249.00) 220.50a,b,c,e) (129.00–273.00) 222.50a,b,c) (165.00–290.00) 235.00a,b,c) (155–301) 219.00a,b,c) (143.00–347.00)
LDL (mg/dL) 77.50 (52.40–126.40) 102.0a) (66.00–124.60) 96.50 (31.80–124.40) 131.40a,b,c) (105.00–168.00) 150.80a,b,c) (59.00–170.00) 150.00a,b,c) (59.00–192.80) 133.00a,b,c) (73.60–263.20) 144.80a,b,c) (82.00–189.60) 146.90a,b,c) (78.60–216.00)
HDL (mg/dL) 45.50 (32.00–59.00) 41.00 (31.00–62.00) 48.00 (33.00–71.00) 42.00 (30.00–69.00) 40.00 (28.00–53.00) 43.00 (31.00–62.00) 47.50 (35.00–67.00) 56.00 (36.00–79.00) 45.00 (29.00–68.00)
TC/HDL 3.14 (2.46–5.59) 4.08a) (2.34–6.29) 3.51 (2.08–4.74) 5.07a) (3.79–7.25) 5.11a) (3.31–7.16) 5.25a) (3.15–7.45) 4.79a) (3.33–6.20) 4.00 (2.87–8.14) 4.65a) (2.96–9.00)
VLDL (mg/dL) 19.30 (9.80–54.00) 22.80 (14.00–41.00) 17.40b) (8.00–43.20) 27.00a,b,c) (13.00–99.40) 30.20a,b,c) (16.20–57.40) 25.00a,c) (10.20–74.00) 26.50a,b,c) (11.60–86.20) 30.20a,b,c) (12.00–110.80) 23.30a,c) (9.00–147.00)
TRG (mg/dL) 96.50 (43.00–257.00) 110.00 (68.00–200.00) 86.00b) (40.00–206.00) 149.00a,b,c) (67.00–215.00) 142.00a,b,c) (81.00–287.00) 125.00a,c) (51.00–365.00) 132.50a,b,c) (58.00–353.00) 151.00a,b,c) (64.00–554.00) 119.00a,c) (45.00–686.00)
MPO (ng/mL) 40.66 (8.79–146.40) 38.02 (14.59–118.88) 76.46a,b) (12.89–142.20) 47.82c) (10.51–95.56) 49.80c) (9.83–136.69) 72.06a,b,d,e) (8.22–309.20) 51.91 (10.23–227.92) 55.46 (10.45–136.64) 66.04 (10.71–141.68)
OxLDL (ng/mL) 156.03 (97.69–299.32) 199.55 (47.20–439.80) 132.04b) (15.45–351.34) 192.97c) (70.22–6849.97) 231.46c) (51.57–666.95) 143.11b,d,e) (66.79–1852.88) 288.66c,f) (107.21–2036.63) 293.68c,f) (82.68–887.31) 168.51c,f) (52.18–1612.88)
Anti-oxLDL (mU/mL) 49.01 (6.26–205.35) 48.91 (4.64–215.31) 21.80a,b) (4.85–190.21) 47.91c) (8.28–119.89) 50.10c) (1.41–163.63) 26.89a,b,d,e) (1.41–123.78) 39.28c) (10.70–132.26) 29.23 (0.61–239.05) 32.10c,f) (10.52–259.06)

Data are shown as median (25%–75%).

Ch: systemically healthy control and gingival health, Cg: systemically healthy control and gingivitis, Cp: systemically healthy control and periodontitis, H1h: hyperlipidemic patients with mild-to-moderate metabolic control and gingival health, H1g: hyperlipidemic patients with mild-to-moderate metabolic control and gingivitis, H1p: hyperlipidemic patients with mild-to-moderate metabolic control and periodontitis, H2h: hyperlipidemic patients with poor metabolic control and gingival health, H2g: hyperlipidemic patients with poor metabolic control and gingivitis, H2p: hyperlipidemic patients with poor metabolic control and periodontitis, TC: total cholesterol, LDL: low-density lipoprotein, HDL: high-density lipoprotein, TC/HDL: ratio of total cholesterol to high-density lipoprotein, VLDL: very low-density lipoprotein, TRG: triglyceride, MPO: myeloperoxidase, oxLDL: oxidized low-density lipoprotein, anti-oxLDL: anti-oxidized low-density lipoprotein.

a)Significant difference from the Ch group (P<0.05); b)Significant difference from the Cg group (P<0.05); c)Significant difference from the Cp group (P<0.05); d)Significant difference from the H1h group (P<0.05); e)Significant difference from the H1g group (P<0.05); f)Significant difference from the H1p group (P<0.05).